Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy
- PDF / 1,243,265 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 12 Downloads / 165 Views
ORIGINAL ARTICLE – CANCER RESEARCH
Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy Yasir G. Malik1,2 · Lars Gustav Lyckander3 · Jonas C. Lindstrøm4 · Olof Vinge‑Holmquist1 · Ariba E. Sheikh1 · Johannes K. Schultz1 · Dejan Ignjatovic1,2 Received: 4 June 2020 / Accepted: 1 September 2020 © The Author(s) 2020
Abstract Purpose Adjuvant chemotherapy for colon cancer with lymph node involvement (Stage III) has been the standard of care since the 1990s. Meanwhile, considerable evolvement of surgery combined with dedicated histopathological examinations may have led to stage migration. Furthermore, prognostic factors other than lymph node involvement have proven to affect overall survival. Thus, adjuvant chemotherapy in Stage III colon cancer should be reconsidered. The objective was to compare recurrence rates and survival in stage III colon cancer patients treated with or without adjuvant chemotherapy. Further, to assess the impact of extensive mesenterectomy, lymph node stage and vascular invasion on outcome. Methods Consecutive patients operated for Stage III colon carcinoma between 31 December 2005 and 31 December 2015 were identified in the pathological code register by matching colon (T67) and either adenocarcinoma (M81403) or mucinous adenocarcinoma (M84803), with lymph node (T08) and metastasis of adenocarcinoma (M81406 or M84806). Medical records of all identified patients were reviewed. Results Of 216 identified patients, 69 received no postoperative adjuvant chemotherapy (group NC), 69 insufficient adjuvant chemotherapy (FLV or
Data Loading...
